Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
CJ HealthCare Corp. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'CJ HealthCare Corp. - Product Pipeline Review - 2016', provides an overview of the CJ HealthCare Corp.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CJ HealthCare Corp., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of CJ HealthCare Corp. - The report provides overview of CJ HealthCare Corp. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses CJ HealthCare Corp.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features CJ HealthCare Corp.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate CJ HealthCare Corp.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for CJ HealthCare Corp. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding CJ HealthCare Corp.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 CJ HealthCare Corp. Snapshot 6 CJ HealthCare Corp. Overview 6 Key Information 6 Key Facts 6 CJ HealthCare Corp. - Research and Development Overview 7 Key Therapeutic Areas 7 CJ HealthCare Corp. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 CJ HealthCare Corp. - Pipeline Products Glance 15 CJ HealthCare Corp. - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 CJ HealthCare Corp. - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 CJ HealthCare Corp. - Early Stage Pipeline Products 19 IND/CTA Filed Products/Combination Treatment Modalities 19 Preclinical Products/Combination Treatment Modalities 20 Discovery Products/Combination Treatment Modalities 21 CJ HealthCare Corp. - Drug Profiles 22 (ezetimibe + rosuvastatin calcium) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 (amlodipine besylate + candesartan cilexetil) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 (amlodipine besylate + rosuvastatin calcium + valsartan) 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 (atorvastatin calcium + metformin hydrochloride) XR 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 tegoprazan 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CJ-40006 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 darbepoetin alfa 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 (amlodipine besylate + atorvastatin calcium + valsartan) 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 somatropin biobetter 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 NSI-566 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CJ-14199 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CJ-40010 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CJ-40011 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 RQ-00000010 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 RQ-00000774 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ranibizumab biosimilar 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CJ HealthCare Corp. - Pipeline Analysis 40 CJ HealthCare Corp. - Pipeline Products by Target 40 CJ HealthCare Corp. - Pipeline Products by Route of Administration 42 CJ HealthCare Corp. - Pipeline Products by Molecule Type 43 CJ HealthCare Corp. - Pipeline Products by Mechanism of Action 44 CJ HealthCare Corp. - Recent Pipeline Updates 46 CJ HealthCare Corp. - Dormant Projects 55 CJ HealthCare Corp. - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
CJ HealthCare Corp., Key Information 6 CJ HealthCare Corp., Key Facts 6 CJ HealthCare Corp. - Pipeline by Indication, 2016 9 CJ HealthCare Corp. - Pipeline by Stage of Development, 2016 10 CJ HealthCare Corp. - Monotherapy Products in Pipeline, 2016 11 CJ HealthCare Corp. - Combination Treatment Modalities in Pipeline, 2016 12 CJ HealthCare Corp. - Partnered Products in Pipeline, 2016 13 CJ HealthCare Corp. - Partnered Products/ Combination Treatment Modalities, 2016 14 CJ HealthCare Corp. - Pre-Registration, 2016 15 CJ HealthCare Corp. - Phase III, 2016 16 CJ HealthCare Corp. - Phase II, 2016 17 CJ HealthCare Corp. - Phase I, 2016 18 CJ HealthCare Corp. - IND/CTA Filed, 2016 19 CJ HealthCare Corp. - Preclinical, 2016 20 CJ HealthCare Corp. - Discovery, 2016 21 CJ HealthCare Corp. - Pipeline by Target, 2016 41 CJ HealthCare Corp. - Pipeline by Route of Administration, 2016 42 CJ HealthCare Corp. - Pipeline by Molecule Type, 2016 43 CJ HealthCare Corp. - Pipeline Products by Mechanism of Action, 2016 45 CJ HealthCare Corp. - Recent Pipeline Updates, 2016 46 CJ HealthCare Corp. - Dormant Developmental Projects,2016 55 CJ HealthCare Corp., Other Locations 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
